- Home
- BBIO vs COKE Comparison
BBIO vs COKE Comparison
Compare BBIO & COKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBIO | COKE |
|---|---|---|
| Founded | 2015 | 1902 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 13.4B |
| IPO Year | 2019 | 1994 |
Fundamental Metrics
Financial Performance| Metric | BBIO | COKE |
|---|---|---|
| Price | $82.40 | $188.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 25 | 0 |
| Target Price | ★ $86.33 | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 489.0K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.50% |
| EPS Growth | N/A | ★ 156.81 |
| EPS | N/A | ★ 1.21 |
| Revenue | $502,076,000.00 | ★ $7,228,055,000.00 |
| Revenue This Year | $89.45 | N/A |
| Revenue Next Year | $73.78 | N/A |
| P/E Ratio | ★ N/A | $152.68 |
| Revenue Growth | ★ 126.26 | 4.76 |
| 52 Week Low | $45.42 | $110.60 |
| 52 Week High | $93.42 | $218.73 |
Technical Indicators
Market Signals| Indicator | BBIO | COKE |
|---|---|---|
| Relative Strength Index (RSI) | 56.36 | 51.93 |
| Support Level | $78.98 | $183.60 |
| Resistance Level | $85.34 | $197.95 |
| Average True Range (ATR) | 2.27 | 6.11 |
| MACD | -0.65 | -0.10 |
| Stochastic Oscillator | 47.73 | 44.55 |
Price Performance
Historical ComparisonAbout BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About COKE Coca-Cola Consolidated Inc.
Coca-Cola Consolidated Inc distributes, markets, and manufactures nonalcoholic beverages. It offers a range of nonalcoholic beverage products and flavors, including both sparkling and still beverages. Sparkling beverages are carbonated beverages, and the Company's principal sparkling beverage is Coca-Cola. Still beverages include energy products and non-carbonated beverages such as bottled water, ready-to-drink tea, ready-to-drink coffee, enhanced water, juices, and sports drinks. The Company has two operating segments: Nonalcoholic Beverages and All Other. Key revenue is generated from Nonalcoholic Beverages.